Tu Wei, Nie Daan, Chen Yuxue, Wen Cheng, Zeng Zhipeng
Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
J Pers Med. 2023 Mar 13;13(3):516. doi: 10.3390/jpm13030516.
Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is characterized by a wide range of dermatological and musculoskeletal manifestations, and its outcome has recently been improved greatly by optimizing management. However, the treatment strategies are not standardized and require further refinement. Secukinumab, a fully human monoclonal antibody targeting IL-17A, is approved for the treatment of autoimmune psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Here, a 53-year-old man was diagnosed with AS, and he presented scattered pustulosis in both hands and feet with a 5-year history of recurrent lumbosacral area pain and abnormal pain in the neck and front chest area. Secukinumab improved the patient's cutaneous lesion and prevented musculoskeletal pain by substituting adalimumab. Although only a few cases have been reported that secukinumab can effectively treat SAPHO syndrome complicated with AS, the efficacy remains controversial. Therefore, we hope to provide a novel valuable therapeutic strategy for SAPHO syndrome management, particularly in patients with skin lesions.
滑膜炎、痤疮、脓疱病、骨肥厚和骨炎（SAPHO）综合征的特点是有广泛的皮肤和肌肉骨骼表现，最近通过优化管理其预后有了很大改善。然而，治疗策略并不规范，需要进一步完善。司库奇尤单抗是一种靶向白细胞介素-17A的全人单克隆抗体，已被批准用于治疗自身免疫性银屑病、银屑病关节炎（PsA）和强直性脊柱炎（AS）。在此，一名53岁男性被诊断为AS，他双手和双足出现散在脓疱病，有5年复发性腰骶部疼痛及颈部和前胸区域疼痛异常的病史。司库奇尤单抗替代阿达木单抗改善了患者的皮肤病变并预防了肌肉骨骼疼痛。尽管仅有少数病例报道司库奇尤单抗可有效治疗合并AS的SAPHO综合征，但其疗效仍存在争议。因此，我们希望为SAPHO综合征的管理，尤其是有皮肤病变的患者提供一种新的有价值的治疗策略。
